hotspot -WSS

hotspot

author：leisure time 2025-10-02 18:50:00 - browse：73

Two boxes of Humira and a Humira pen on the side — first opinion coverage from STAT — David J. Phillip/AP

It’s been one year since the launch of the first adalimumab biosimilar for Humira in the United States, which was followed by eight additional adalimumab biosimilar launches. These nine FDA-approved products offer lower-cost alternatives to the world’s bestselling drug, Humira, used to treat rheumatoid arthritis, Crohn’s disease, and other autoimmune disorders. This made 2023 a watershed year for millions of U.S. patients paying too much for their necessary medications.

But so far, that vision hasn’t come to fruition, because policymakers haven’t taken the action necessary to be sure these lower-cost products are accessible for patients. If they fail to act, the U.S. health care system could lose up to $133 billion in savings and leave patients without access to the medicines they need.

Biosimilars are safe and effective treatments referencing biologic drugs. They are market disruptors, forcing lower prices for biologic medicines. The cost savings from reference biologic products begins almost immediately when biosimilars enter the market and continues over time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： European regulators recommend Amylyx's ALS drug be rejected

hotspot

WSS

How doctors and nurses shape Google's AI

To bolster infectious disease surveillance, genomics powerhouses team up

Peter Marks talks Operation Warp Speed for Rare Diseases

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

Dog Aging Project founders on what lies ahead after losing funding

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Wikipedia

hotspot

focus

Medical records are filled with copy

Takeaways from AdvaMed, the largest medical devices conference

Cancer drug shortages should be causing more outrage

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Psychedelics group wrestles with new pharma identity

Nick Jonas talks about managing diabetes along with his career

Wildfire smoke exposes gaps in outdoor worker protections

Prior authorization reform is both possible and imperative

BioMarin wins approval for gene therapy to treat hemophilia A

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

hotspot

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Humana CEO Bruce Broussard to step down in 2024

High breast density mammograms need follow

How should state employee insurance handle Wegovy?

Nick Jonas talks about managing diabetes along with his career

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

entertainment

focus

hotspot

leisure time